subscribe: Posts | Comments

Leukemia Drug Halts And Reverses MS Symptoms

Leukemia Drug Halts And Reverses MS Symptoms

Leukemia drug, Alemtuzumab, is proving to be the most effective experimental drug for the treatment of Multiple Sclerosis.

British researchers have found that a drug, originally designed for the treatment of lymphocytic leukemia, can halt and even reverse the debilitating effects of multiple sclerosis.

The drug known as Alemtuzumab, has shown to reduce the number of attacks in sufferers and has also helped them regain lost functions, allowing damaged brain tissue to repair so that individuals were less disabled than at the start of the study.

leukemia drug cures ms Leukemia Drug Halts And Reverses MS Symptoms

“The ability of an MS drug to promote brain repair is unprecedented,”

Said Dr Alasdair Coles, a lecturer at Cambridge University’s department of clinical neurosciences and coordinated of the study.

“We are witnessing a drug which, if given early enough, might effectively stop the advancement of the disease and also restore lost function by promoting repair of the damaged brain tissue.”

He added.

The MS society Britain’s largest support charity for those affected by the condition is delighted with studies results. Head researcher Lee Dunster said,

“This is the first drug that has shown the potential to halt and even reverse the debilitating effects of MS and this news will rightly bring hope to people living with the condition day in, day out,”

MS is an auto-immune disease that affects millions of people worldwide. By causing the body’s immune system to attack nerve fibers in the central nervous system, the disease can lead to loss of sight and mobility, depression, fatigue and cognitive problems.

The study was conducted on 334 patients who been diagnosed with early-stage relapsing-remitting MS but had not previously been treated. The participants were given Alemtuzumab or interferon beta-1a, one of the current most effective therapies for MS cases.

After three years, Alemtuzumab was found to reduce the number of attacks the patients suffered by 74 per cent over the other treatment, it also reduced the risk of sustained accumulation of disability by 71 per cent.

Many of the individuals who took Alemtuzumab also recovered some of their lost functions, becoming less disabled by the end, while the disabilities of the other patients worsened.

Professor of neurology and head of the clinical neurosciences department at Cambridge, Alastair Compston, said, Alemtuzumab was the “most promising” experimental drug for the treatment of MS. He expressed hope that,

“[Further trials] will confirm that it can both stabilize and allow some recovery of what had previously been assumed to be irreversible disabilities”.


Related posts:


, , , , , ,


  1. Unavailable, please contact us for more information.

Comments are closed.